Literature DB >> 6781321

Increased exercise tolerance after oral diltiazem, a calcium antagonist, in angina pectoris.

Y Koiwaya, M Nakamura, A Mitsutake, S Tanaka, A Takeshita.   

Abstract

Effects of diltiazem, a recently introduced calcium antagonist, on exercise performance were studied in nine coronary disease patients with effort angina. The duration of exercise before the onset of angina and the time to the onset of ischemic ST depression 2 hours after 90 mg of oral diltiazem were compared with those 2 hours after oral placebo and a few minutes after 0.3 mg of sublingual nitroglycerin. Diltiazem prolonged the duration of exercise in all nine patients (average 2.5 minutes, p less than 0.001) and delayed the onset of ischemic ST depression (average 2.4 minutes, p less than 0.001). The increment of the duration of exercise and the time to the onset of ischemic ST depression following 90 mg of oral diltiazem were almost equivalent to that following sublingual nitroglycerin. These results in fixed coronary atherosclerosis indicate the clinical antianginal efficacy of diltiazem which persists for at least 2 hours after oral administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6781321     DOI: 10.1016/0002-8703(81)90656-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Immediate and long-term effects of nicardipine, at rest and during exercise, in patients with coronary artery disease.

Authors:  C A Visser; W Jaarsma; G Kan; J J Koolen; K I Lie
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 2.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

3.  Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 4.  Role of calcium channel blockers in experimental exercise-induced ischemia.

Authors:  E Thaulow; B D Guth; J Ross
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 5.  Calcium antagonists. Clinical use in the treatment of angina.

Authors:  P Théroux; Y Taeymans; D D Waters
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

6.  Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.

Authors:  W P Klinke; M Baird; M Juneau; D Waters; W Warnica; Z Lakhani; L Annable; A P Boulet; L Larivière
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.